Updates on Liquid Biopsy for Advanced NSCLC: A Consensus Statement from the IASLC
Webinar | English | 1 Hr 08 Min
Image For Activity Cover
Credit Offered
No Credit Offered
There have been major advancements in therapies and diagnostics for advanced-stage non-small-cell lung cancer over the past few years and these have led to meaningful increases in survival. One of the biggest advances is in therapeutics and diagnostics for molecular alterations that drive the oncogenic process. Tumor tissue has been the accepted standard biospecimen but there can be limitations with tissue, including collection and analysis. Thus, liquid biopsy, primarily blood plasma, represents a practical alternative source for determining tumor-derived somatic alterations.

This webinar will feature interactive case-based panel discussions to review the state of the field for liquid biopsy in NSCLC and discuss the standard of care recommendations for a global audience that were proposed in the recently published IASLC consensus statement on liquid biopsy. This webinar is designed to meet the educational needs of physicians, nurses and allied health professionals, pharmacists, patient advocates, and researchers who specialize in diagnostic radiology, pulmonary medicine, medical oncology, thoracic surgery, radiation oncology, pathology, and cancer research/basic sciences.
Christian Rolfo, MD, PhD, MBA, Dr.hc.

Consultant: EMD Serono, Pfizer, Mirati, Eisai, Daiichi Sankyo, Sanofi Genzyme-Regeneron
Speakers Bureau: Astra Zeneca, Roche, COR2ED
David R. Gandara, MD

Advisory Board: Roche Genentech, Merck, Novartis, Boehringer Ingelheim, Regeneron, Sanofi, Amgen
Research Grant: Amgen, Astex, Genentech
Consultant: Adagene, Astra Zeneca, IO Biotech, Guardant Health, Oncocyte
Natasha B. Leighl, MD, MMSc, FRCPC, FASCO

Research Funding from Ineligible Companies: Amgen, Array, Astra Zeneca, Bayer, BMS, Eli Lilly, EMD Serono, Guardant Health, Inivata, MSD, Novartis, Pfizer, Roche, Takeda
Honoraria for CME: BMS, MSD, Novartis, Takeda, Sanofi Genzyme
Consultant: CADTH, EMD Serono, GlaxoSmithKline, Puma Biotechnology
Murry Wynes, PhD

Nothing to Disclose
All other planners, reviewers and staff reported no relevant financial relationships.

All relevant financial relationships have been mitigated.
At the end of the webinar, learners will be able to:
Review the updated IASLC Consensus Recommendations for the Use of Liquid Biopsy in NSCLC
Recognize clinical situations when liquid biopsy may improve lung cancer patient outcomes
Powered By